|By PR Newswire||
|March 5, 2014 03:02 AM EST||
DUBLIN, March 5, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/885sfr/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering.
Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.
A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease.
With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III.
The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.
Key Topics Covered:
1. EXECUTIVE SUMMARY
3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES
4. CURRENT MARKET AND FORECAST
5. TECHNOLOGY PLATFORMS
6. PROFILES OF LEADING COMPANIES
7. SWOT ANALYSIS
9. LIST OF COMPANIES AND ORGANISATIONS
- Boehringer Ingelheim
- Chiome Bioscience
- Dow Pharma
- EMD Serono
- Eli Lilly
- Epigen Biotech
- Fabion Pharmaceuticals
- Imclone Systems
- Mitsubishi Tanabe
- Molecular Partners AG
- OtSuka Pharma
- Paktis Antibody Services GmbH
- Tanabe Research Labs
- X-Body Biosciences
For more information visit http://www.researchandmarkets.com/research/885sfr/bispecific
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
Jun. 3, 2015 04:00 PM EDT Reads: 1,078
Jun. 3, 2015 04:00 PM EDT Reads: 2,227
Jun. 3, 2015 04:00 PM EDT Reads: 4,998
Jun. 3, 2015 04:00 PM EDT Reads: 1,146
Jun. 3, 2015 04:00 PM EDT Reads: 615
Jun. 3, 2015 04:00 PM EDT Reads: 596
Jun. 3, 2015 03:45 PM EDT Reads: 1,763
Jun. 3, 2015 03:45 PM EDT Reads: 839
Jun. 3, 2015 03:30 PM EDT Reads: 706
Jun. 3, 2015 03:30 PM EDT Reads: 594
Jun. 3, 2015 03:15 PM EDT Reads: 3,992
Jun. 3, 2015 03:00 PM EDT Reads: 3,847
Jun. 3, 2015 03:00 PM EDT Reads: 403
Based upon his work with progressive brands, thought-leader and author of the book, Big Social Mobile, David Giannetto, SVP at Salient Management Company, will provide his unique perspective on how companies of tomorrow will operate as enterprises that seamlessly follow consumers from the physical world, through digital creating a multichannel omni-experience that improves the customer experience while increasing their brand loyalty, customer value and penetrating new consumer segments. His se...
Jun. 3, 2015 03:00 PM EDT Reads: 762
SYS-CON Events announced today DevOps.com will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Launched in 2014, DevOps.com has quickly established itself as an indispensable resource for DevOps education and community building. DevOps.com make it their mission to cover all aspects of DevOps – philosophy, tools, business impact, best practices and more.
Jun. 3, 2015 02:45 PM EDT Reads: 709